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The pulmonary collectin, surfactant protein A (SP-A), is a broad spectrum opsonin with microbicidal membrane
permeabilization properties that plays a role in the innate immune response of the lung. However, the factors that
govern SP-A’s microbial specificity and the mechanisms by which it mediates membrane permeabilization and
opsonization are not fully understood. In an effort to identify bacterial factors that confer susceptibility or resistance to
SP-A, we used comparative signature-tagged mutagenesis to screen a library of 1,680 Pseudomonas aeruginosa
mutants for evidence of differential pulmonary clearance in SP-A-sufficient (SP-A
þ/þ) and SP-A-deficient (SP-A
 / ) mice.
Two SP-A-sensitive P. aeruginosa mutants harboring transposon insertions in genes required for salicylate biosynthesis
(pch) and phosphoenolpyruvate-protein-phosphotransferase (ptsP) were recovered. The mutants were indistinguish-
able from the parental wild-type PA01 with regard to opsonization by SP-A, but they exhibited increased susceptibility
to SP-A-mediated membrane permeabilization. These results suggest that bacterial gene functions that are required to
maintain membrane integrity play crucial roles in resistance of P. aeruginosa to the permeabilizing effects of SP-A.
Citation: Zhang S, Chen Y, Potvin E, Sanschagrin F, Levesque RC, et al. (2005) Comparative signature-tagged mutagenesis identifies Pseudomonas factors conferring
resistance to the pulmonary collectin SP-A. PLoS Pathog 1(3): e31.
Introduction
Pulmonary surfactant is a protein-phospholipid complex
that lines the air-liquid interface of alveoli, forming the ﬁrst
point of contact with inhaled microbial pathogens [1,2]. A
multitude of in vitro studies have demonstrated that the
pulmonary collectins, surfactant protein A (SP-A) and
surfactant protein D (SP-D), bind and aggregate bacterial,
fungal, viral, and mycobacterial organisms, directly activate
macrophages, and enhance the in vitro phagocytosis and
intracellular killing of a variety of pulmonary pathogens [3,4].
Recognition of diverse microbial species by the pulmonary
collectins is mediated by the C-type lectin domain, which
selectively binds to carbohydrates that are prevalent on the
surface of microbes, but not to the predominant terminal
sugars on surface molecules of mammalian cells [5]. More
recently, SP-A and SP-D have been reported to possess potent
antimicrobial properties [6–8]. They directly inhibit the
proliferation of bacteria and fungi in a macrophage- and
aggregation-independent manner, by increasing the perme-
ability of the microbial cell membrane. In particular, rough
strains of Gram-negative bacteria, containing truncated
lipopolysaccharide (LPS) domains are uniquely vulnerable
to permeabilization by the collectins [6], as has been well
known for other antimicrobial peptides and proteins.
Although the collectins inhibit microbial growth, the
factors that govern the speciﬁcity and the mechanisms of
membrane disruption by the collectins are not understood. In
this study, we employed comparative signature-tagged muta-
genesis (STM) as a tool to identify bacterial factors required
to resist SP-A-mediated clearance, in vivo. STM relies on the
ability of the pathogen in question to replicate in vivo as a
mixed population and allows for the identiﬁcation of the
mutants whose phenotypes cannot be trans-complemented
by other virulent strains present in the same inoculum [9].
Two Pseudomonas factors that are speciﬁcally required to




 /  Mice Are Susceptible to Infection by P. aeruginosa
Levine et al [10] have reported that outbred SP-A
 /  mice
exhibit delayed clearance of a clinical P. aeruginosa strain from
the lung, suggesting that SP-A plays a role in pulmonary
innate immunity against this organism. We also found that
the inbred C3H/HeN SP-A
 /  mice were more susceptible to
P. aeruginosa infection, in this case by strain PA01. SP-A
þ/þ
mice cleared 63-fold (1.8 log) more of intranasally inoculated
PA01 by 16 h (Figure 1A). In contrast, the bacterial load
increased by 22 fold (1.34 log) in SP-A
 /  mice (Figure 1A). In
the absence of infection, SP-A
 /  mice are healthy, and the
histopathological analyses of their non-infected lungs re-
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of SP-A
þ/þ mice (unpublished data). When infected with PA01
however, SP-A
þ/þ mice developed broncho-pneumonia with
mild pulmonary inﬁltrates (Figure 1B). In contrast, SP-A
 / 
mice developed more extensive consolidation with areas of
lobar pneumonia.
Identification of P. aeruginosa Genes Conferring
Resistance to SP-A by Comparative STM Screening
We exploited the PCR-based STM technique and the P.
aeruginosa PA01 STM mutant library [11] to identify putative
microbial targets for SP-A. SP-A
þ/þ and SP-A
 /  mice, in
groups of three, were intranasally challenged with pools of 72
oligo-tagged STM mutants. Lungs were harvested at 16 h,
homogenized, and plated. At least 10,000 bacterial colonies
grown on Luria broth (LB) agar plates were harvested from
each lung for bacterial genomic DNA extractions and oligo-
tag ampliﬁcation. We screened for differential clearance of




 / mice (Figure 2A, see arrows), we postulated
that the bacterial protein encoded by the mutated gene was
required to overcome the host defense activities of SP-A.
We comparatively screened 1,680 STM mutant strains in
SP-A
þ/þ and SP-A
 /  mice. Two mutants with increased
sensitivity to SP-A (i.e., failed to survive in SP-A
þ/þ mice)
were recovered, for a 0.12% recovery rate. We have cloned
and sequenced both STM mutants by plasmid rescue [11].
DNA sequences were analyzed by comparison with online
databases (www.pseudomonas.com). The output from Pool 4
(mutant pch, see below) is shown in Figure 2B (left panel). In
the presence of SP-A, the pch mutant, which is disrupted in a
gene required for salicylate biosynthesis, was unable to
survive in the SP-A
þ/þ lung (missing band in the box, Figure
2B). In absence of SP-A, the pch mutant was able to grow in
the lung, as indicated by the presence of an oligo-tag
ampliﬁed by PCR (Figure 2B, left panel, SP-A
 /  lane; right
panel, lane m1). The results were conﬁrmed by PCR analysis
of the output pool of two additional mice (Figure 2B, right
panel, lanes m2 and m3).
The pch STM mutant carries a transposon pUTmi-
niTn5Km2 insertion within an intergenic region in between
the 10
th and 11
th nucleotide after the stop codon of the pchA
(PA4231) gene (Figure 2C). The pchA gene encodes an
isochorismate synthase that participates in the biosynthesis
of the siderophores, salicylate, and pyochelin [12–14].
Because transposon inserted within the intergenic region
immediately downstream of the pchA gene, it might have
affected the mRNA stability of the pchDCBA transcript. Thus,
we named the STM mutant as pch. We examined whether the
pch mutant had lost the ability to synthesize pyochelin by
using thin layer chromatography (TLC) assays. TLC analysis
of pyochelin extracted from bacteria cultured in M63
minimal medium conﬁrmed that the pch mutant is unable
to synthesize the green-colored pyochelin (Figure 2D, pch
lane). In contrast, the parental wild-type PA01 produced
pyochelin (Figure 2D, PA01 lane). When the pch STM mutant
was grown in the presence of 1 mM salicylate, however, the
ability to synthesize pyochelin was restored (Figure 2D, pch þ
1mM salicylate lane). The expression of the genes within the
downstream operon (PA4232 and PA4233), which is tran-
scribed in opposite orientation to the pchADCBA operon, was
found to be unaffected by transposon insertion as assessed by




 /  mice (group of six) were infected intranasally
with 1 3 10
7 P. aeruginosa PA01. Bacteria were recovered from
homogenized lung tissue 16 h after inoculation. p , 0.01.
(B) Representative lung histology sections (stained with hematoxylin and
eosin) from SP-A
þ/þ and SP-A /  mice 16 h post intranasal instillation of
PA01. Original magnification: 10 3.
DOI: 10.1371/journal.ppat.0010031.g001
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Synopsis
Everyday, normal breathing deposits numerous microorganisms on
the surfactant membrane that lines the air-exchanging surfaces of
the lung. Surfactant protein SP-A, a component of the surfactant
membrane, helps to maintain the lung in a germ-free state by
aggregating inhaled microorganisms and facilitating their ingestion
by immune cells, and by increasing the permeability of their cell
membranes. However, the bacterial pathogen Pseudomonas aerugi-
nosa is resistant to SP-A-mediated membrane disruption.
Using a genetic tool called comparative signature-tagged muta-
genesis, the authors have identified two P. aeruginosa genes, pch
and ptsP, that are required to resist SP-A-mediated membrane
permeabilization. Molecular analyses indicate that the pch gene
encodes an enzyme that synthesizes salicylate, a compound utilized
by bacteria to acquire essential metal ions. The ptsP gene encodes
an enzyme called phosphoenolpyruvate-protein-phosphotransfer-
ase. The loss of salicylate and phosphoenolpyruvate-protein-
phosphotransferase weakens the P. aeruginosa cell membrane,
which allows SP-A to poke holes on the membrane and kill the
bacteria.
This is the first known report of the roles played by salicylate and
phosphoenolpyruvate-protein-phosphotransferase in maintenance
of bacterial membrane, and consequently, protecting bacteria from
killing by SP-A, through disruption of membrane integrity.mRNA expression analyses (unpublished data). Collectively,
these data suggest that susceptibility to SP-A-mediated
clearance is caused by the loss of pch gene function, most
probably by affecting the mRNA stability of the pchDCBA
operon.
The second SP-A-susceptible STM mutant had the trans-
poson pUTminiTn5Km2 inserted in between the 2,213
th and
2,214
th nucleotides of the ptsP (PA0337) gene (Figure 2C). The
ptsP gene encodes a phosphoenolpyruvate-protein-phospho-
transferase, a homolog of the E. coli Enzyme I
nitrogen (EI
Ntr)
[15]. The transposon pUTminiTn5Km2 insertion into ptsP is
predicted to cause polarity and interrupt the transcription of
PA0338.
Both STM mutants were judged to harbor a single trans-
poson pUTminiTn5Km2 insertion after hybridization with
the transposon vector (unpublished data). DNA fragments
that ﬂanked both ends of the transposon integrations in pchA
and ptsP genes were cloned from the wild-type PA01. They
were used to conﬁrm gene interruption by the integrating
transposon, by comparing restriction fragment length poly-
Figure 2. PCR-Based Signature-Tagged Mutagenesis
(A) Schematic drawing of PCR-based STM. Pools of 72 uniquely tagged mutants were intranasally inoculated into SP-A
þ/þ and SP-A
 /  mice; 16 h later,
lungs were harvested, homogenized, and plated. Approximately 10,000 colonies were harvested from the plates for genomic DNA extraction. PCR-
amplification of tags was performed on the genomic DNA to screen for the presence or absence of DNA tags of each of the 72 mutants. Mutants whose
DNA tags were present in the input pool and in the SP-A
 /  pool, but absent in the SP-A
þ/þ pool (see white arrows) were further screened for
susceptibility to SP-A.
(B) Agarose gel of PCR-based STM, identifying the pch mutant (left panel). Attenuation in the first SP-A
þ/þmouse (right panel, m1) was confirmed in two
additional SP-A
þ/þ mice (right panel, m2 and m3).
(C) Genetic loci of P. aeruginosa, when mutated, conferred increased sensitivity to in vivo killing by SP-A. DNA regions flanking pUTmini-Tn5 transposon
insertions were cloned and sequenced. Similarity BLAST searches were performed against P. aeruginosa PA01 genomic sequence on NCBI and on
www.pseudomonas.com. Black arrows indicate the approximate insertion site within the mutated ORFS.
(D) TLC analyses indicate that the pch STM mutant is unable to synthesize pyochelin (see arrows). Wild-type PA01 grown in LB and the pch mutant
grown in LB supplemented with 1 mM salicylate produced green color pyochelin (see arrows). In contrast, no observable pyochelin was produced by
the pch and PA06331 strains. Pure pyochelin was used as control.
(E) Restriction fragment length polymorphism analysis between parental wild-type PA01 and STM mutants confirmed that mutations in pch and ptsP
were caused by a single insertion.
DOI: 10.1371/journal.ppat.0010031.g002
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mutants. As shown in Figure 2E, transposon-ﬂanking DNA
probes hybridized to DNA fragments with higher molecular
weights in the chromosomes of both the pch and ptsP mutants
than their parental strain PA01, indicating transposon
insertion.
SP-A-Sensitive STM Mutants Are as Virulent as Parental
Wild-Type in SP-A
 /  Mice
Apart from confronting pulmonary host defenses, our STM
screens require each mutant to compete with 71 other STM
mutants within individual library pools. Competitive mixed
infection assays have been widely used to assess the ﬁtness of
individual mutants versus their parental strains during in vivo
infection [16,17]. As shown in Figure 3A, when co-adminis-
tered with the parental wild-type PA01 by intranasal inocu-
lation intomice,both STMmutants werelesscompetitive than
PA01 in SP-A
þ/þmice. Speciﬁcally, mutant strains pch and ptsP
were only 53% and 46% as competitive as PA01, respectively.
In contrast, both mutants performed equally well as, if not
better than, the wild-type strain in SP-A
 /  mice (Figure 3A).
We further tested the mutants, pch and ptsP, in single
infection studies. When infected singly into wild-type mice,
the viable bacterial counts of pch and ptsP mutant bacteria
were 32-fold (1.5 log) and 25-fold (1.4 log) higher, respec-
tively, in SP-A
 /  mice than in SP-A
þ/þ mice (Figure 3B). Our
results indicate that SP-A plays an important role in
clearance of PA01 mutants with defective pch or ptsP gene
function.
Preferential Clearance of the STM Mutants from SP-A
þ/þ
Lung Is Independent of Macrophages
Previous studies have suggested that SP-A opsonizes P.
aeruginosa and increases uptake by macrophages [10,18]. To
determine if SP-A-mediated opsonization contributes to the
early clearance of STM mutants, we compared the phagocy-
tosis of pch and ptsP to PA01 in the presence and absence of
SP-A. When live, green ﬂuorescence protein (GFP)-expressing
bacteria were exposed to mouse alveolar macrophages in the
presence of SP-A, the uptake of PA01, its pch, or ptsP mutant
was increased by 1.8, 1.3, and 1.6 fold, respectively, over that
which occurred in the absence of SP-A (Figure 4A). However,
the SP-A mediated increase in opsonization was only statisti-
cally signiﬁcant in PA01 (p,0.01). The magnitude of the
increase in the uptake of PA01 in the presence of SP-A was
similar to previously published reports [10,18]. Although the
addition of SP-A increased the macrophage uptake of STM
mutants, enhancement of phagocytosis was slightly lower
than that of wild-type PA01. Therefore, it does not appear
that SP-A-mediated opsonization is responsible for the
preferential clearance of pch and ptsP mutants from SP-A
þ/þ
mice.
Figure 3. SP-A-Sensitive P. aeruginosa STM Mutants Compete Effectively
with Parental Wild-Type PA01 in SP-A
 /  , but Not in SP-A
þ/þ Mice
(A) In vivo competition assays between the wild-type and individual STM
mutants after intranasal pulmonary inoculation of 6-wk-old SP-A
þ/þ and
SP-A
 /  mice. The mean CFU recovered from four mice in each group is
shown. The CI is defined as the output ratio of mutant to wild-type
bacteria divided by the input ratio of mutant to wild-type bacteria. *p ,
0.013, #p , 0.011.
(B) Single respiratory tract infection of pch and ptsP mutants in SP-A
þ/þ
and SP-A
 / mice was performed as described for Figure 1. Attenuation is
defined as the log10 difference in CFU between wild-type and mutant
bacteria recovered from lung tissue 16 h after inoculation. The mean 6
standard error of six mice is shown. *p , 0.019, #p , 0.045.
DOI: 10.1371/journal.ppat.0010031.g003
Figure 4. Bacterial Opsonization by SP-A Does Not Result in Differential
In Vivo Phagocytosis and Killing of STM Mutants
(A) In vitro phagocytosis assays were performed using live, GFP-
expressing PA01 and isogenic pch and ptsP bacteria, with alveolar
macrophages isolated from SP-A
þ/þ mice. Internalized bacteria were
counted using a phase contrast fluorescence microscope. The means of
three experiments are shown. Two hundred macrophages were counted
for each mouse. p¼0.0058 (PA01 vs PA01þSP-A), p¼0.075 (pch vs pchþ
SP-A), and p ¼ 0.109 (ptsP vs ptsP þ SP-A).
(B) In vitro phagocytosis of PA01, pch, and ptsP by human neutrophils
isolated from healthy volunteers. Phagocytosis experiments were
performed as described for (A). p ¼ 0.037 (PA01 vs PA01 þ SP-A), p ¼
0.577 (pch vs pch þ SP-A), and p ¼ 0.919 (ptsP vs ptsP þ SP-A).
(C–E) SP-A did not affect uptake or killing of STM mutants. PA01 (C), but
not the STM mutants pch (D) and ptsP (E) were killed in significant
amounts by neutrophils, independent of SP-A. The mean of three
separate experiments is shown. p , 0.001 when comparing PA01 versus
PA01þneutrophils, and when comparing PA01-SP-A versus PA01-SP-Aþ
neutrophils.
DOI: 10.1371/journal.ppat.0010031.g004
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þ/þLung
Is Independent of Neutrophils
Neutrophils are known to play a major role in protecting
the lung against bacterial infection. We examined whether
bacterial phagocytosis and killing by neutrophils might have
led to preferential clearance of pch and ptsP. As shown in
Figure 4B, the uptake of PA01 and the pch and ptsP mutants
was not increased in the presence of SP-A. In fact, SP-A-
opsonized PA01 bacteria were phagocytosed less efﬁciently by
neutrophils than untreated bacteria. Interestingly, only wild-
type PA01 bacteria were susceptible to killing by neutrophils,
with approximately 73.7% killed in the absence of SP-A, and
57.2% killed in the presence of SP-A (Figure 4C). In contrast,
both pch and ptsP mutants were not susceptible to neutrophil
killing (Figure 4D and 4E). These results indicate that
neutrophils kill P. aeruginosa by using a mechanism independ-
ent of SP-A opsonization, and lend support to the notion that
neutrophils play a less critical role in the preferential
clearance of pch and ptsP mutants from the SP-A
þ/þ mice
than other anti-pseudomonal mechanisms.
The Loss of pch and ptsP Gene Functions Render P.
aeruginosa Susceptible to SP-A-Mediated Membrane
Permeabilization
Recent studies have indicated that SP-A is capable of
directly killing bacteria and fungi by membrane permeabili-
zation and inhibition of macro-molecular synthesis, inde-
pendent of macrophage-mediated phagocytosis [6,7]. We
examined whether direct membrane permeabilization con-
tributed to the clearance of the SP-A-sensitive mutants. Due
to the previously described importance of LPS in resistance
to SP-A-mediated membrane permeabilization [6,19], we used
a LPS mutant wbpL, which is deﬁcient in the production of
‘‘initial’’ glycosyltransferase essential for the biosynthesis of
both the A-band and B-band O-antigen of LPS [20], as
positive control for membrane permeabilization assays.
Permeabilization of the wbpL mutant was approximately
2.7-fold greater than the wild-type strain PA01 at 60 min
(Figure 5A). In contrast, STMG2A7, an irrelevant mutant that
is virulent in both SP-A
þ/þ and SP-A
 /  mice, was found to be
as resistant as parental wild-type PA01 to SP-A-mediated
membrane permeability (Figure 5B).
The STM mutant pch, and a mutant strain, PA06331, in
which the pyochelin biosynthetic genes encompassing
pchDCBA, pchR, and pchEFGHI operons had been removed
[14], were permeabilized by SP-A to an extent that was 3.4-
and 2.55-fold greater than the wild-type strain PA01,
respectively (Figure 5C and 5D) after 60–90 min exposure
to SP-A. Similarly, STM mutant ptsP, and an in-frame,
nonpolar deletion mutant, DptsP, were permeabilized by SP-
A to an extent that was 3.0- and 3.8-fold greater than the wild-
type strain PA01, respectively (Figure 5E and 5F), at 60–90
min post-exposure to SP-A. These data are comparable to the
approximately 3-fold increase in membrane permeability
that SP-A exposure induces in E. coli K12 [6].
SP-A-Mediated Membrane Permeabilization Directly Kills
the pch and ptsP Mutants
We next determined if SP-A mediated permeability kills
STM mutants. Live/dead staining, based on exclusion of
propidium iodide from the live cells, was performed on
bacterial cells following membrane permeability assays.
Viable cells are stained green while dead cells are stained
red. As shown in Figure 6A, SP-A did not kill wild-type PA01
(green stained). In contrast, mixtures of green- and red-
stained cells of pch and ptsP were visible following treatment
with SP-A. Approximately 11% and 9 % of pch and ptsP cells,
respectively, were killed (Figure 6B) within 60 min, in
comparison to about 40% of E. coli K12 (unpublished data).
In addition, in contrast to the robust SP-A-induced aggrega-
tion of E. coli K12 (Figure 6A), SP-A did not aggregate P.
aeruginosa PA01, pch, or ptsP. These results suggest that the loss
of intact LPS (i.e. rough LPS), or the inability to synthesize
Figure 5. The pch and ptsP Mutants Are Preferentially Permeabilized and
Killed by SP-A
(A) Fluorescence of a cleavage-activated phosphatase substrate ELF97
was examined in the presence or absence of 50 lg hSP-A for a period of
60–90 min. Human SP-A (hSP-A) preferentially permeabilized LPS mutant
wbpL, but not the parental wild-type PA01. The wbpL strain was used as
positive control for membrane permeability. The difference in membrane
permeabilization between wbpL mutant and PA01 was significant from
the 28
th min onward. *p , 0.05.
(B) A mutant strain STMG2A7 that is virulent in both SP-A
þ/þ and SP-A
 / 
mice was as resistant to SP-A-mediated membrane permeabilization as
the parental wild-type PA01.
(C–D) Membrane permeability of the STM mutant pch and PA06331,aP.
aeruginosa strain which is deleted in all of the structural genes required
for pyochelin biosynthesis (Table 1.). The difference in membrane
permeabilization between the mutants against wild-type PA01 was
significant from the 35
th and 18
th min onward for mutant strains pch and
PA06331, respectively. *p , 0.05.
(E–F) Membrane permeability of the STM mutant ptsP and the DptsP, a P.
aeruginosa strain with a nonpolar, inframe deletion of the ptsP gene. The
difference in membrane permeabilization between the mutants against
wild-type PA01 was significant from the 29
th and 28
th min onward, for
mutant strains ptsP and DptsP, respectively. *p , 0.05.
DOI: 10.1371/journal.ppat.0010031.g005
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ferase, renders the cells vulnerable to membrane permeabi-
lization and killing by SP-A. Furthermore, bacterial
aggregation does not play a role in preferential clearance of
the pch and ptsP mutants.
Complementation of the pch and ptsP Mutants Restores
Their Resistance to SP-A-Mediated Membrane
Permeabilization
The susceptibility of STM mutants to SP-A mediated
membrane permeabilization can be exploited for comple-
mentation analyses. As the pch mutant is disrupted in a gene
required for salicylate biosynthesis, we performed comple-
mentation analysis by growing the pch mutant bacteria in the
presence of 1 mM sodium salicylate. As shown in Figure 7A,
the pch mutant bacteria grown in LB were susceptible to SP-
A-mediated membrane permeabilization. In contrast, the pch
mutant bacteria grown in LB supplemented with 1 mM
sodium salicylate were fully resistant to membrane perme-
abilization by SP-A. We further examined whether the
increased susceptibility to SP-A-mediated membrane perme-
ability was due to the inability pch bacteria to synthesize the
siderophore pyochelin. The pch bacteria cultured in pyoche-
lin-supplemented LB or iron-deﬁcient minimal medium were
still membrane permeabilized by SP-A (unpublished data).
Collectively, these results suggest that the increased suscept-
ibility to SP-A-mediated membrane permeability in the pch
bacteria is due to their inability to synthesize salicylate, or
both salicylate and pyochelin. However, we cannot com-
pletely rule out the possibility that pyochelin may be involved
in resistance to SP-A-mediated membrane permeability until
we have exhausted all the growth conditions and optimal
pyochelin concentrations for the assays.
To rule out the possibility that 1 mM sodium salicylate may
inactivate the enzymatic activity of the periplasmic phospha-
tases that cleaves the impermeant substrate, ELF97, in our
permeability assay, we also tested ptsP mutant bacteria
cultured in the presence or absence of 1 mM sodium
salicylate. The ptsP mutant bacteria were permeabilized to
the same extent, regardless of whether they were grown in the
presence or absence of 1 mM sodium salicylate (Figure 7B),
suggesting that salicylate did not inactivate phosphatase.
These results suggest that the loss of pch gene function results
in susceptibility of P. aeruginosa to clearance by SP-A by
rendering the organism susceptible to membrane permeabi-
lization.
We next tested if providing the wild-type ptsP gene in trans
to the ptsP STM mutant bacteria could restore the resistance
to SP-A-mediated membrane permeabilization. As shown in
Figure 7C, the resulting strain, pUCP-ptsP was as resistant to
SP-A-mediated membrane permeabilization as the wild-type
PA01. In contrast, providing an irrelevant gfp gene in the ptsP
bacteria (ptsP-gfp) did not restore the resistance of ptsP STM
mutant to SP-A, nor did it alter the resistance or suscepti-
bility of the parental wild-type PA01 (PA01-gfp) to permeabi-
lization by SP-A (Figure 7C). These results suggest that ptsP
gene function protects P. aeruginosa from membrane perme-
abilization by SP-A.
Figure 6. SP-A-Mediated Membrane Permeabilization Directly Kills the pch and ptsP Mutants
(A) Live/Dead staining was performed on E. coli K12, PA01, pch, and ptsP cells, following 1 h membrane permeabilization with 100 lg/ml SP-A. Green-
stained cells are alive whereas red-stained cells are dead.
(B) Enumeration of live or dead bacteria following a 1 h exposure to hSP-A. At least 600–1,000 bacterial cells were counted under a fluorescence
microscope. The mean of two experiments is shown.
DOI: 10.1371/journal.ppat.0010031.g006
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Previous studies in E. coli [6] and Bordetella pertussis [19] have
demonstrated that the structures of LPS on the surface of
bacterial cells determine resistance to SP-A-mediated aggre-
gation and membrane permeabilization. P. aeruginosa LPS
mutants are also sensitive to SP-A-mediated membrane
permeability, but are not aggregated by the collectin (Figure
5A; unpublished data). To examine if the pch and ptsp mutants
have LPS defects, we compared the LPS proﬁles after
separation by SDS-PAGE and silver staining. The LPS from
wild-type PA01 and the pch mutant were indistinguishable
(unpublished data). However, the two major LPS core bands
of the ptsP mutant showed a reversal in relative abundance
compared with the PA01 (unpublished data). Thus, there may
be changes in LPS, at least in terms of the proportion of two
different cores made. More detailed molecular analyses will
be required to determine if LPS modiﬁcation occurs within
pch and ptsP mutants.
Discussion
The genome-wide mutagenesis scheme called STM was
originally developed to identify novel vaccine and antibiotic
targets [9]. STM relies on the ability of the pathogen in
question to replicate in vivo as a mixed population, and
allows the identiﬁcation of the virulence genes whose mutant
phenotypes cannot be trans-complemented by other virulent
strains present in the same inoculum. Hundreds of virulence
factors and putative drug targets have been identiﬁed by STM
in at least 20 different bacterial and fungal pathogens [21]. In
all of these screens, a pathogen of interest is mutated by
transposon or suicide vector-based insertional strategies. The
vectors are each individually tagged with a DNA oligonucleo-
tide to allow mutant identiﬁcation after selection within the
host. Attenuated insertion mutants that are killed by host
defense mechanisms such as exposure to SP-A, will fail to
amplify from lung homogenates harvested 16 h after intra-
tracheal inoculation (Figure 2A). Comparative STM screening
using wild-type and genetically altered mice, as presented
herein, represents a novel application of the STM technique.
This approach allows the identiﬁcation of bacterial determi-
nants targeted by speciﬁc components of host defense, rather
than the entire immune system as a whole. Thus, in contrast
to conventional STM screens in wild-type mice, which yield
an attenuated mutant recovery rate of 2%–10% [21], our
comparative STM screen to identify factors that protect
bacteria against a speciﬁc host innate immunity protein, SP-
A, had a yield of only 0.12%. As STM screens, by deﬁnition,
only recover mutations in non-essential genes, another
reason for detecting few mutants in this screen is that these
genes involved in resistance to SP-A may be essential.
In this study, we have employed STM technology to identify
bacterial factors that are required for P. aeruginosa strain
PA01 to confer resistance to SP-A. Both mutants were
susceptible to SP-A-mediated membrane permeabilization,
conﬁrming that disruption of membrane integrity is one of
the mechanisms by which SP-A mediates bacterial clearance.
The degree of bacterial membrane permeabilization of the
STM mutants by SP-A was comparable to that of E. coli K12,
which has rough LPS [6]. Based on the results of in vitro
assays, macrophages and neutrophils do not seem to play
important roles in preferential clearance of the pch and ptsP
mutants. However, we cannot exclude the possibility that
phagocytosis contributes to the differential clearance of these
two mutants in vivo.
Thus far, we have not recovered STM mutants that are
susceptible to SP-A-mediated opsonization, or mutants that
are disrupted in the genes required for LPS biosynthesis,
which play critical roles in resistance to SP-A-mediated
membrane permeability. The lack of recovery of opsoniza-
tion-sensitive and LPS mutants are not particularly surpris-
ing, considering that we screened only approximately 30% of
the 5,570 mutants required for 1 3 genome coverage
(www.pseudomonas.com). Additional screenings are being
carried out to catalog other P. aeruginosa factors conferring
resistance to SP-A.
The mechanisms by which mutations in pch and ptsP genes
result in susceptibility to SP-A-mediated clearance are brieﬂy
discussed below. The pchDCBA gene encodes enzymes
involved in the synthesis of iron-chelating siderophores
salicylate and pyochelin [12–14]. In another closely related
pathogen, Burkholderia cepacia, salicylate is a major side-
rophore [22]. Salicylate has also been reported to chelate
magnesium (Mg
2þ) and calcium [23]. Thus, it is possible that P.
aeruginosa requires salicylate and its downstream product
Figure 7. Complementation Studies of SP-A-Sensitive Mutants pch and
ptsP
(A) Culturing pch bacteria in LB supplemented with sodium salicylate
restored its resistance to SP-A mediated membrane permeabilization.
(B) In control experiments, we demonstrated that the enzymatic activity
of bacterial phosphatases in ptsP bacterial cells was not inhibited by 1
mM sodium salicylate.
(C) Provision of the wild-type ptsP gene on the pUCP19 in trans (pUCP-
ptsP) restores the ability of STM mutant ptsP to resist SP-A mediated
membrane permeabilization. In contrast, ptsP mutant expressing GFP
gene on the pUCP19 (pstP-gfp) is permeabilized to similar levels as ptsP.
DOI: 10.1371/journal.ppat.0010031.g007
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Mg
2þ, are required to structurally stabilize LPS on the outer
membrane. The recently resolved structure of SP-A protein
indicates that there are two metal binding domains within SP-
A, which are most likely occupied by calcium [24]. Thus, SP-A
may sequester cations from alveolar lining ﬂuid and result in
a growth disadvantage for the salicylate-deﬁcient pch mutant.
Furthermore, inability to acquire cations may potentially
alter the expression, stability, and modiﬁcation of various
transmembrane proteins and glycolipids by enzymes that
require cations as cofactors. Thus, we speculate that the pch
mutation may have contributed to its increased sensitivity to
SP-A-mediated membrane permeabilization through direct
or indirect effects on LPS integrity and membrane stability.
The ptsP gene encodes phosphoenolpyruvate-protein
phosphotransferase EI
Ntr [15], a transcriptional regulator of
RpoN-dependent operons [25]. RpoN is known to regulate
the expression of variety of virulence factors in pathogenic
bacteria, including the upregulation of the rfaH gene, which is
required for increased production of the O-antigen of LPS in
Salmonella enterica serovar Typhi during the stationary phase of
growth [25]. The additional O-antigen production during the
stationary phase of bacterial growth may be necessary for
resistance to SP-A-mediated membrane permeabilization.
PtsP also coordinates carbon and nitrogen metabolism and
is required for virulence in P. aeruginosa, by an unknown
mechanism [26]. Mutational inactivation of the Azotobacter
vinelandii ptsP ortholog affects lipidic poly-hydroxybutyrate
accumulation within its cytoplasm as a carbon source for
long-term starvation survival [27]. Interestingly, poly-hydrox-
ybutyrate is found in the plasma membranes of E. coli
complexed to calcium polyphosphate, and forms divalent
cation-selective channels [28]. Thus, increased sensitivity to
SP-A-mediated membrane permeabilization in ptsP mutants
may be caused by its reduced ability to transport divalent
cations necessary to maintain LPS and outer membrane
integrity.
Our results suggest that the killing of P. aeruginosa PA01 and
STM mutants is more robust in vivo than in vitro. One
potential explanation for this discrepancy is that our in vitro
membrane permeability conditions do not accurately model
the environment in the lung. In addition, it is possible that
multiple factors contribute to the killing of P. aeruginosa
including SP-A, SP-D, lactoferrin, b-defensins, and other
antimicrobial peptides and proteins [29,30]. We are currently
examining whether these peptides act synergistically or
cooperatively with SP-A in clearance of P. aeruginosa.
Decreased SP-A levels have been found in several respira-
tory diseases including bacterial pneumonia, adult respira-
tory distress syndrome [31,32], and cystic ﬁbrosis [33–35].
There is some in vitro evidence to suggest that decreased SP-
A and SP-D levels in some of these disease states result from
degradation by neutrophil proteases of the host [36,37], or by
proteases of bacterial origin [38]. These proteases include
bacterial elastases, and neutrophil-derived cathepsin G,
elastase, and proteinase-3. The reduced levels of SP-A and
SP-D in these lung diseases may contribute to increased
susceptibility to infections by variety of microbial pathogens.
Degradation of SP-A by P. aeruginosa proteases may also
explain our failure to develop informative in vitro STM
screens (unpublished data).
Antibiotic-resistant P. aeruginosa is an emerging clinical
problem that can lead to denial for lung transplantation and
death [39]. Thus, there is an added urgency to explore the use
of novel, non-antibiotic-based, anti-Pseudomonal peptides to
combat life-threatening infections with this organism. The
discovery of factors governing resistance or susceptibility to
SP-A may ultimately have therapeutic value.
Materials and Methods
Bacterial strains, media, and growth conditions. Shaking cultures
of E. coli DH5-a [40], SM17kpir [41], and P. aeruginosa strain PA01 [42]
were grown in LB broth at 37 8C. When needed, LB was supplemented
with 1.5% of bacto agar. Antibiotic selections were performed for E.
coli or P. aeruginosa using the following concentrations: carbenicillin
(50 or 300 lg/ml), kanamycin (50 or 250 lg/ml), and tetracycline (5 or
15–30 lg/ml).
Animal husbandry. The C3H/HeN SP-A
 /  mice were developed as
previously described [6,7]. C3H/HeN control (SP-A
þ/þ) mice were
purchased from Charles River Laboratory (Boston, Massachusetts,
United States). All infections were performed intranasally with age-
matched, 6-wk-old mice. Animals were housed in positively ventilated
microisolator cages with automatic recirculating water, located in a
room with laminar, high-efﬁciency, particle accumulation-ﬁltered air.
The animals received autoclaved food, water, and bedding. Mice used
in experimental procedures were handled in accordance with
Table 1. Bacterial Strains and Plasmids Used in this Work
Bacterial Strains Relevant Characteristics Reference
E. coli
DH5a F-f80 DlacZDM15 endA1 recA1 hsdR17 (r
 km
þk) supe44 thi-1 l-gyr A96 relA1 D(lacZYA-argF) U169 [40]
SM17kpir F
 araD D(lac pro) argE(Am) recA56 rif
r nalA [41]
P. aeruginosa
PA01 Wild-type prototrophic laboratory strain [42]
PA01-gfp PA01 harboring pUCP19-gfp This study
Pch PA01 miniTn5Km2pch, salicylate and siderophore biosynthesis mutant This study
PA06331 PA01 harboring deletions in pchDCBA, pchR,a n dpchEFGHI genes [14]
ptsP PA01 miniTn5Km2ptsP, phosphoenolpyruvate phosphotransferase mutant This study
pUCP-ptsP PA01 miniTn5Km2ptsP expressing the wild-type ptsP gene on the pUCP19 plasmid This study
DptsP PA01 harboring non-polar deletion in ptsP gene This study
Plasmids
pUCP19 polylinker lacZ, lac
iq selection, bla [44]
pEX18T polylinker lacZa, bla, sacB [43]
DOI: 10.1371/journal.ppat.0010031.t001
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Committee at University of Cincinnati College of Medicine.
Comparative screening of the P. aeruginosa STM library in SP-A
þ/þ
and SP-A
 /  mice. The P. aeruginosa PA01 STM library and screening
methods were previously described [11]. An adapted acute mouse
lung pneumonia model of infection was employed, where adult mice
rather than the infant mice were used [16]. In earlier experiments, we
detected no signiﬁcant difference in SP-A expression by ELISA assays
at 8, 16, and 24 h in SP-A
þ/þ mouse lungs infected with bacteria (1 3
10
7 cells) from a representative pool of STM library (unpublished
data). We chose the 16 h time point to screen the STM library because
it gave us the most reproducible PCR ampliﬁcation of DNA tags from
mutants, with   10,000 colony forming units (CFU) still recoverable
from the SP-A
þ/þ mice (unpublished data). In contrast, prolonged
infection (  36 h) with 1 3 10
7 bacteria from STM pool frequently
killed SP-A
 /  mice (unpublished data). Brieﬂy, SP-A
þ/þ and SP-A
 / 
mice [6,7] were anaesthetized using isoﬂuorane, and were intranasally
inoculated with 50 ll( 13 10
7 cells) of each individual STM pool.
After 16 h, lungs were removed from sacriﬁced mice, and
homogenized tissues were plated on LB agar plates. At least 10,000
bacterial colonies recovered after in vivo selection were used for
multiplex PCR as described previously [11]. Twenty sets of 72 mutants
(total ¼ 1,440) were pooled and screened. An additional 240 mutants
previously shown to be attenuated in a chronic model of rat lung
infection [11] were also screened. The mutants that were differ-
entially cleared by SP-A during the in vivo passaging were
subsequently retested by single PCR in bacterial cells recovered from
three separate mice.
In vivo competitive and single infection assays. For competition
assays, mouse lungs were inoculated intranasally with bacterial cells (1
3 10
7 in 50 ll) composed of a 1:1 ratio of wild-type PA01 and its
isogenic STM mutants. Infected lungs were recovered 16 h after
infection for bacterial load determination. The competitive index
(CI) is deﬁned as the output ratio of mutant to wild-type bacteria
divided by the input ratio of mutant to wild-type bacteria [16,17].
Thus, if a mutant strain is less competitive than the parental strain
from which it was derived, a CI value of , 1 will be achieved,
indicating that the mutant is attenuated. Single organism inocu-
lations with individual bacterial strains were performed by the
intranasal route in SP-A
þ/þ and SP-A
 /  mice (group of six).
Attenuation was deﬁned as the log10 difference in CFU between
wild-type and mutant bacteria recovered from lung tissue 16 h after
inoculation.
Mutant cloning and bioinformatics analysis. Cloning of putative
STM mutants were performed as previously described [11]. The DNA
sequences were analyzed with MacVector or DNA Star software.
Sequence data was compared with the database available for P.
aeruginosa at http://www.pseudomonas.com.
Non-polar deletion and complementation of the ptsP mutant. Non-
polar, in-frame deletion of ptsP was generated by PCR: 0.802 and
1.155-kb 59 and 39 segments were ampliﬁed from target PA01
genomic DNA, and each amplicon, which included an engineered
restriction site, was ligated into pEX18Ap [43] to produce replace-
ment plasmids. Inframe deletion mutants were generated in PA01 via
homologous recombination by sucrose resistance selection, and
conﬁrmed by hybridization and PCR analysis (unpublished data).
To complement the ptsP mutation, a 4.5-kb DNA fragment containing
both the promoter and the ygdP-ptsP-PA0338 operon (Figure 2C) was
PCR-ampliﬁed from the wild-type parental strain PA01 using the
Expand Long Template PCR System (Roche Diagnostic, Basel,
Switzerland), and cloned into E. coli-P. aeruginosa shuttle plasmid
pUCP19 [44] to obtain pUCP19-ptsP. The cloned fragment was
sequenced to rule out any mutation that was introduced during the
ampliﬁcation. The pUCP19-ptsP was introduced into P. aeruginosa
STM mutant strain ptsP by heat shock. Carbenicillin-resistant
transformants were selected, and veriﬁed by Southern hybridization
and PCR methods (unpublished data). Complementation was assessed
by resistance to SP-A-mediated membrane permeabilization.
Complementation of the pch STM mutant. Complementation of the
pch mutant was performed by culturing the bacteria into stationary
phase in LB supplemented with 1 mM sodium salicylate.
Pyochelin extraction and detection. Pyochelin production in P.
aeruginosa was analyzed using the method previously described [45].
M63 minimal medium (5 ml) was inoculated with fresh colonies of
individual P. aeruginosa strains and incubated at 37 8C for 24 h with
shaking. A fresh 30 ml of M63 supplemented with 0.5% w/v casamino
acids was then inoculated with 0.3 ml of starter culture, and
incubated for 36 h at 37 8C with shaking. The culture was then
centrifuged at 13,000 rpm for 10 min in 1.5 ml aliquots in a
microcentrifuge. The supernatants were removed into a 50 ml
polypropylene screw-capped centrifuge tube, pooled, adjusted to (pH
2.0) with 1M HCl, using universal indicator paper to estimate pH, and
ﬁlter sterilized through a 0.22 lM membrane. Pyochelin was extracted
by the addition of 0.4 volumes of ethyl acetate, followed by vigorous
vortexing. The two phases were separated by centrifugation at 2,000
rpm for 5 min in a bench top centrifuge, and the upper, organic
phase was removed to a separate tube. Pyochelin extract was
concentrated by rotary evaporation at 40 8C in 100 ml round
bottomed ﬂasks, and the residue was dissolved in 300 ll of methanol.
Pyochelin extracts (10 ll) was separated by TLC (silica gel 60, plastic
backed, from Sigma, St. Louis, Missouri, United States), using
acetone:methanol:0.2M acetic acid (5:2:1) as a development solvent.
The chromatography tank was left to stand for several minutes with
its lid on to allow the air inside to become saturated with solvent
vapor. Pyochelin, which is ﬂuorescent, naturally occurs as two
stereoisomers. When visualized under a UV transilluminator, it is
revealed as two green ﬂuorescent bands. Pyochelin standard was
generously provided by Dr. J. M. Meyer (Universite ´ Louis Pasteur).
Puriﬁcation of human SP-A. Human SP-A (hSP-A) was puriﬁed
from lung washings of patients with the lung disease alveolar
proteinosis, as previously described [6]. SP-A preparations were re-
suspended in 5 mM Tris, 150 mM NaCl. SP-A preparations were
determined to contain 140–190 pg of LPS/lg of SP-A by the Limulus
Amebocyte Lysate (BioWhittaker, Rockland, Maryland, United
States).
Assays of P. aeruginosa permeability. The effect of the SP-A on P.
aeruginosa cell wall integrity was assessed by determining permeability
to a phosphatase activity substrate, Enzyme-Labeled Fluorescence 97
(ELF-97, Molecular Probes, Eugene, Oregon, United States) as
described [7]. SP-A was incubated with 1 3 10
8 bacterial cells/ml in
100 ll of 5 mM Tris, 150 mM NaCl for 15 min at 37 8C, and 100 lM
ELF97 phosphatase substrate was added. Fluorescence was measured
at excitation and emission wavelengths of 355 and 535 nm,
respectively, for a period of 60–90 min.
In vitro macrophage and neutrophil phagocytosis assays. Freshly
lavaged mouse macrophages (; 5 3 105 from 3 SPA
þ/þ mice) were
cultured on chamber plastic culture slides, coated with 5% poly-D-
lysine with 200 ll RPMI (Dulbecco’s, containing 2.5 mg/L gentamycin
and 0.1% BSA) and used immediately. Macrophages were allowed to
adhere for 2 h at 37 8Ci n5 %C O 2. Live GFP-expressing PA01 or
isogenic STM mutants in RPMI were opsonized with or without 25 lg/
ml human SP-A for 1 h at 37 8C with rotation. The medium was
removed from each well and replaced with 250 ll of opsonized PA01
or STM mutants, and incubated for 1 h at 37 8Ci n5 %C O 2 at a ratio
of 100 bacteria to 1 macrophage. Chamber slides were washed three
times with PBS containing 1 mM CaCl2. Extracellular bacteria were
quenched with crystal violet (0.8 mg/ml). Following two additional
washes, cells were ﬁxed with 1% paraformaldehyde in PBS plus 1 mM
CaCl2 for 10 min, and stained with Evans blue for 2 min. The
percentage of macrophages with engulfed bacteria was quantiﬁed
under a phase contrast ﬂuorescence microscope. At least 200
macrophages were counted. Human neutrophils were puriﬁed and
cultured as previously described [46]. Neutrophil phagocytosis was
performed as described for macrophages.
LIVE/DEAD bacterial staining. The viability of SP-A exposed
bacteria was determined by LIVE/DEAD Baclight
TM Bacterial
Viability Kit (Molecular Probes). Brieﬂy, stationary phase E. coli or
P. aeruginosa bacteria were washed three times with 5 mM Tris, 150
mM NaCl, and adjusted to an of OD600 ¼ 1.0. A 100-ll aliquot of the
cells was added to culture tubes containing 100 ll of SP-A (100 lg/ml)
or 100 ll of 5 mM Tris, 150 mM NaCl, as a control. The mixtures were
incubated at 37 8C, 300 rpm for 1 h, and stained according to the
instructions provided by the supplier. The viability of the cells was
checked under a ﬂuorescence microscope. At least 1, 000 cells were
counted.
LPS preparations. LPS was isolated from P. aeruginosa by acetone/
phenol extraction [47]. LPS samples were size-fractionated on 4%–
12% Bis-Tris PAGE gels (NuPAGE Novex Gels; Invitrogen, San Diego,
California, United States) and stained with silver.
Statistical analysis. Statistical analysis was performed using the
Student’s t-test and one-way analyses of variance (ANOVA). A
signiﬁcant difference was considered to be p , 0.05.
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